Stryker

$Stryker(SYK.US) | Piper Sandler reiterates 𝐎𝐯𝐞𝐫𝐰𝐞𝐢𝐠𝐡𝐭 on 𝐒𝐭𝐫𝐲𝐤𝐞𝐫, maintains 𝐏𝐓 𝐚𝐭 $𝟒𝟐𝟎

Analyst sees SYK as the standout in its market, expecting continued share gains in hips and knees driven by its Mako robot's strong execution.

$Stryker(SYK.US) | Argus reiterates 𝐁𝐮𝐲 on 𝐒𝐭𝐫𝐲𝐤𝐞𝐫, 𝐫𝐚𝐢𝐬𝐞𝐬 𝐏𝐓 𝐭𝐨 $𝟑𝟕𝟎

Analyst sees SYK overcoming cyberattack disruptions to post stronger H2 2026 growth, driven by its Mako V4 launch and diversified portfolio.

$Stryker(SYK.US) | Leerink 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧𝐬 𝐎𝐮𝐭𝐩𝐞𝐫𝐟𝐨𝐫𝐦 on 𝐒𝐭𝐫𝐲𝐤𝐞𝐫, 𝐭𝐫𝐢𝐦𝐬 𝐏𝐓 𝐭𝐨 $𝟒𝟎𝟕

Analyst sees a positive risk/reward skew, believing Stryker remains one of the best-positioned large-cap MedTech names despite minor estimate revisions.